Frizzled-7-targeted delivery of zinc oxide nanoparticles to drug-resistant breast cancer cells
- 28 May 2019
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 11 (27) , 12858-12870
Abstract
There is a need for novel strategies to treat aggressive breast cancer subtypes and overcome drug resistance. ZnO nanoparticles (NPs) have potential in cancer therapy due to their ability to potently and selectively induce cancer cell apoptosis. Here, we tested the in vitro chemotherapeutic efficacy of ZnONPs loaded via a mesoporous silica nanolayer (MSN) towards drug-sensitive breast cancer cells (MCF-7: estrogen receptor-positive, CAL51: triple-negative) and their drug-resistant counterparts (MCF-7TX, CALDOX). ZnO-MSNs were coated on to gold nanostars (AuNSs) for future imaging capabilities in the NIR-II range. Electron and confocal microscopy showed that MSN–ZnO–AuNSs accumulated close to the plasma membrane and were internalized by cells. High-resolution electron microscopy showed that MSN coating degraded outside the cells, releasing ZnONPs that interacted with cell membranes. MSN–ZnO–AuNSs efficiently reduced the viability of all cell lines, and CAL51/CALDOX cells were more susceptible than MCF7/MCF-7-TX cells. MSN–ZnO–AuNSs were then conjugated with the antibody to Frizzled-7 (FZD-7), the receptor upregulated by several breast cancer cells. We used the disulphide (S–S) linker that could be cleaved with a high concentration of glutathione normally observed within cancer cells, releasing Zn2+ into the cytoplasm. FZD-7 targeting resulted in approximately three-fold amplified toxicity of MSN–ZnO–AuNSs towards the MCF-7TX drug-resistant cell line with the highest FZD-7 expression. This study shows that ZnO-MSs are promising tools to treat triple-negative and drug-resistant breast cancers and highlights the potential clinical utility of FZD-7 for delivery of nanomedicines and imaging probes specifically to these cancer types.Keywords
Funding Information
- National Institute for Health Research
- Michael J. Fox Foundation for Parkinson's Research (11713)
This publication has 32 references indexed in Scilit:
- Glutathione levels in human tumorsBiomarkers, 2012
- Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumorsProceedings of the National Academy of Sciences, 2012
- Collateral sensitivity as a strategy against cancer multidrug resistanceDrug Resistance Updates, 2012
- Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysisThe Breast, 2011
- The important role of the apoptotic effects of zinc in the development of cancersJournal of Cellular Biochemistry, 2009
- Preferential killing of cancer cells and activated human T cells using ZnO nanoparticlesNanotechnology, 2008
- Zinc and its transporter ZIP10 are involved in invasive behavior of breast cancer cellsCancer Science, 2007
- Molecular Mechanisms of Ca2+ Signaling in Neurons Induced by the S100A4 ProteinMolecular and Cellular Biology, 2006
- Role of p53 and reactive oxygen species in apoptotic response to copper and zinc in epithelial breast cancer cellsApoptosis, 2005
- Oestrogen-regulated genes in breast cancer: Association of pLIV1 with lymph node involvementEuropean Journal of Cancer, 1994